Results 11 to 20 of about 483,678 (300)
Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Hepatology Communications, 2023 Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic.Aaron Vanderhoff, David Smookler, Mia J. Biondi, Scott Enman, Tintin Fuliang, Sana Mahmood, Agustina Crespi, Maria Marquez, Rafique Van Uum, Lucy You, Brett Wolfson‐Stofko, Renee Logan, Erin LeDrew, Hemant Shah, Harry Janssen, Camelia Capraru, Elisa Venier, Jordan J. Feld +17 moredoaj +2 more sourcesObatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro
Emerging Microbes and Infections, 2022 Coronavirus disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has set off a global pandemic. There is an urgent unmet need for safe, affordable, and effective therapeutics against COVID-19.Binli Mao, Vu Thuy Khanh Le-Trilling, Kai Wang, Denise Mennerich, Jie Hu, Zhenyu Zhao, Jiaxin Zheng, Yingying Deng, Benjamin Katschinski, Shilei Xu, Guiji Zhang, Xuefei Cai, Yuan Hu, Jianwei Wang, Mengji Lu, Ailong Huang, Ni Tang, Mirko Trilling, Yong Lin +18 moredoaj +1 more sourceThe evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]
, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S +12 morecore +3 more sourcesMonitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016) [PDF]
, 2018 Objectives: The World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fast-track action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance.De Brujin, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, Iyengar, World Health Organisation, World Health Organisation, World Health Organisation +11 morecore +1 more sourceAutomated quality control for a molecular surveillance system
BMC Bioinformatics, 2018 Background Molecular surveillance and outbreak investigation are important for elimination of hepatitis C virus (HCV) infection in the United States. A web-based system, Global Hepatitis Outbreak and Surveillance Technology (GHOST), has been developed ...Seth Sims, Atkinson G. Longmire, David S. Campo, Sumathi Ramachandran, Magdalena Medrzycki, Lilia Ganova-Raeva, Yulin Lin, Amanda Sue, Hong Thai, Alexander Zelikovsky, Yury Khudyakov +10 moredoaj +1 more sourceClinical and laboratory characteristics of hepatitis C and COVID‐19 coinfection: Prolonged RNA shedding in nonhospitalized case
Clinical Case Reports, 2021 Nonhospitalized COVID‐19 and hepatitis C‐coinfected patient presented prolonged RNA shedding and mild course of infection. This finding demonstrated the importance of long follow‐up of these patients.Livia Melo Villar, Vanessa Salete dePaula, Laura Cristina Machado Pinto, Bianca Cristina Leires Marques, Vanessa Duarte daCosta, Lucas Lima daSilva, Alanna Calheiros Santos, Giselle Prado doNascimento, Juliana Custódio Miguel, Ana Carolina da Fonseca Mendonça, Fernando Couto Motta, Lia Laura Lewis‐Ximenez +11 moredoaj +1 more sourceAn expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]
, 2018 BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou +173 morecore +2 more sourcesTherapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
Brazilian Journal of Infectious Diseases, 2012 Background: Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 ...Aline Gonzalez Vigani, Eduardo Sellan Gonçales, Maria Helena Postal Pavan, Flavia Genari, Raquel Tozzo, Maria Silvia Kroll Lazarini, Viviane Fais, Adriana Feltrin, Neiva Sellan Gonçales, Fernando Lopes Gonçales, Jr +9 moredoaj +1 more sourceBarriers of linkage to HCV viremia testing among people who inject drugs in Georgia
Substance Abuse Treatment, Prevention, and Policy, 2022 Background People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals.Maia Butsashvili, Tinatin Abzianidze, George Kamkamidze, Lasha Gulbiani, Lia Gvinjilia, Tinatin Kuchuloria, Irina Tskhomelidze, Maka Gogia, Maia Tsereteli, Veronique Miollany, Tamar Kikvidze, Shaun Shadaker, Muazzam Nasrullah, Francisco Averhoff +13 moredoaj +1 more source